Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMSE8NU)

Drug Name
4-ANDROSTENE-3-17-DIONE Drug Info
Synonyms
Androstenedione; androstenedione; 4-Androstene-3,17-dione; Androst-4-ene-3,17-dione; 1963/5/8; 4-Androstenedione; Androtex; 3,17-Dioxoandrost-4-ene; delta-4-Androstenedione; SKF 2170; Fecundin; delta-4-Androsten-3,17-dione; delta-4-Androstene-3,17-dione; Androstendione; 4-Androsten-3,17-dione; NSC 9563; delta-(sup4)-Androsten-3,17-dione; delta(sup 4)-Androstene-3,17-dione; UNII-409J2J96VR; 17-Ketotestosterone; d4-androstenedione; CHEBI:16422; Androstenedione [JAN]; HSDB 7335; EINECS 200-554-5; MLS000028510; NSC9563; ANDROSTENEDIONE
Cross-matching ID
PubChem CID
6128
ChEBI ID
CHEMBL274826
CAS Number
CAS 63-05-8
TTD Drug ID
D0M8RO
VARIDT Drug ID
DR00943
INTEDE Drug ID
DR0116

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Oxidative phosphorylation 2.06 0.00e+0 93/133 (69.92%) COX7B;NDUFB1;ATP5MF;...
Steroid biosynthesis 1.94 2.04e-2 19/20 (95%) SQLE;SC5D;MSMO1;...
Terpenoid backbone biosynthesis 1.91 1.36e-2 18/22 (81.82%) HMGCS1;IDI1;FDPS;...
PPAR signaling pathway 1.89 1.02e-2 66/74 (89.19%) HMGCS1;SCD;ACSL3;...
D-Glutamine and D-glutamate metabolism -1.73 4.79e-2 5/5 (100%) GLS2;GLS;DGLUCY
Bladder cancer -1.75 4.52e-2 40/41 (97.56%) HRAS;THBS1;TP53;...
Proximal tubule bicarbonate reclamation -1.76 4.79e-2 21/23 (91.3%) GLS2;PCK2;GLS;...
Thyroid cancer -1.79 3.59e-2 36/37 (97.3%) RXRB;NTRK1;PPARG;...
Selenocompound metabolism -1.79 4.19e-2 11/17 (64.71%) KYAT3;TXNRD1;PAPSS1;...
Protein digestion and absorption -1.80 4.55e-2 78/103 (75.73%) ATP1A3;COL1A2;ATP1B1;...
Aldosterone-regulated sodium reabsorption -1.85 2.69e-2 34/37 (91.89%) SCNN1A;PRKCB;FXYD2;...
Signaling pathways regulating pluripotency of stem cell... -1.90 2.00e-2 110/143 (76.92%) IGF1R;JAK2;KAT6A;...
Mineral absorption -1.95 1.20e-2 48/60 (80%) ATP7A;MT1HL1;SLC26A3;...
Leishmaniasis -2.03 0.00e+0 67/77 (87.01%) FCGR2C;CYBB;NFKBIA;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
1HAEo- CVCL_0128 Homo sapiens 10uM 24H
NL20 CVCL_0461 Homo sapiens 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Normal (Fibroblast)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HFL1 CVCL_4295 Homo sapiens 10uM 24H
IMR-90 CVCL_0347 Homo sapiens 10uM 24H
WI-38 CVCL_0579 Homo sapiens 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H